Form 8-K - Current report:
SEC Accession No. 0001013762-25-003645
Filing Date
2025-03-28
Accepted
2025-03-28 10:52:41
Documents
15
Period of Report
2025-03-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0235809-8k_lomond.htm   iXBRL 8-K 36859
2 FORM OF AMENDMENT NO. 2 TO SUBSCRIPTION AGREEMENTS, DATED MARCH 24, 2025 ea023580901ex10-1_lomond.htm EX-10.1 16455
3 PRESS RELEASE, DATED MARCH 28, 2025 ea023580901ex99-1_lomond.htm EX-99.1 13874
  Complete submission text file 0001013762-25-003645.txt   249249

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE cik0001900520-20250324.xsd EX-101.SCH 3089
5 XBRL LABEL FILE cik0001900520-20250324_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE cik0001900520-20250324_pre.xml EX-101.PRE 22399
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0235809-8k_lomond_htm.xml XML 3361
Mailing Address C/O LOMOND THERAPEUTICS HOLDINGS, INC. 8 THE GREEN STE 8490 DOVER DE 19901
Business Address C/O LOMOND THERAPEUTICS HOLDINGS, INC. 8 THE GREEN STE 8490 DOVER DE 19901 561 464 2841
Lomond Therapeutics Holdings, Inc. (Filer) CIK: 0001900520 (see all company filings)

EIN.: 872959575 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-56377 | Film No.: 25781909
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)